Elena Pintea

Oct 14
From the pharmacy counter to Swissmedic

From the pharmacy counter to Swissmedic: how a suspected ADR gets reported

Pharmacovigilance does not start in a safety database. It starts when a patient says, "Since I started these tablets, something isn't right." What happens next determines whether that observation becomes useful safety data or is lost.
4 min read
Oct 12
Two ICH guidelines shape how drug developers assess effects on the immune system before human use: ICH S8 for immunotoxicity of pharmaceuticals, and ICH S6(R1) for biotechnology-derived produ

ICH S8 and S6 in plain language: immunotoxicity for small molecules vs biologics

Two ICH guidelines shape how drug developers assess effects on the immune system before human use: ICH S8 for immunotoxicity of pharmaceuticals, and ICH S6(R1) for biotechnology-derived products. They answer the same broad question, but in different ways.
3 min read
Oct 12
Cytokine release

Cytokine release and first-in-human trials: the lessons of TGN1412

In March 2006, six healthy volunteers in London received a new monoclonal antibody called TGN1412. Within hours, all six developed a severe cytokine storm and needed intensive care (Suntharalingam et al., 2006). All survived, but the trial changed how the industry and regulators approach first-in-hu
4 min read
Oct 12
When the immune system is the adverse event

When the immune system is the adverse event: what macrophage research teaches drug safety

My master's thesis at the University of Basel focused on one of those cells: the macrophage. In this article I explain why macrophages matter for drug safety and what laboratory work on them teaches about recognising immune-mediated harm.
4 min read